All patients 
                     adolescents (typically 12-15 years of age)  adults (typically between 18 and 65yr)  age >= 55 yr  age >= 60 yr  age >= 65 yr  age >= 75 yr  alpha variant (B.1.1.7, UK)  any cancer  autoimmune disease  beta variant (B.1.351 / 501Y.V2, South Africa)  children  corticosteroids: no  corticosteroids: yes  critical disease  delta variant (B.1.617.2, Indian)  dialysis patients  elderly (typically over 65yr)  fully vaccinated  gamma variant (P.1, Brazil)  haematological cancers   healthcare workers  immunodepression  invasive ventilation  kidney transplant recipients  no oxygen needed  non invasive oxygen  obese  omicron variant BA.1 (B.1.1.529)  omicron variant BA.2 VOC  original (Wuhan) strain  positive for SARS-Cov-2 at baseline  severe disease  solid cancer  solid organ transplant recipients  subjects at risk  
                  
            
            
         
        
        
        
        
        
        
            potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results  ConPlas-19, 2020 0.56 [0.20; 1.57]
DAWN-Plasma, 2021 0.61 [0.24; 1.55]
NCT04397757, 2021 0.47 [0.04; 5.45]
Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
VERU-111, 2022 0.30 [0.14; 0.64]
 0.62 [0.31 ; 1.24 ] ConPlas-19, 2020, DAWN-Plasma, 2021, NCT04397757, 2021, Sekine (PLACOVID), 2021, VERU-111, 2022 5 51% 1,222 moderate not evaluable death D28detailed results  Abdulamir, 2021 1.00 [0.20; 5.12]
Abuhasira, 2021 0.72 [0.23; 2.24]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
ASCOT, 2021 0.60 [0.06; 5.99]
Bennett-Guerrero, 2021 0.86 [0.24; 3.11]
CAN-COVID, 2020 0.67 [0.30; 1.50]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.12 [0.86; 1.46]
ConPlas-19, 2020 0.49 [0.20; 1.19]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-ANA-1, 2021 0.91 [0.38; 2.19]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
FACCT Trial, 2021 0.69 [0.28; 1.68]
Fragoso-Saavedra (PISCO), 2020 0.32 [0.13; 0.80]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.62 [0.33; 1.17]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50]
GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86]
Gunst JD, 2021 0.99 [0.29; 3.42]
Horby, 2021 1.01 [0.93; 1.10]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
ITAC, 2022 0.80 [0.42; 1.52]
Jamaati, 2021 1.19 [0.38; 3.72]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Kirenga, 2021 1.25 [0.46; 3.39]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Lanzoni, 2021 0.14 [0.02; 0.96]
Li, 2020 0.59 [0.22; 1.59]
LIFESAVER, 2021 2.00 [0.16; 24.66]
Mahajan, 2021 1.23 [0.34; 4.42]
Menichetti, 2021 0.75 [0.37; 1.53]
Metcovid, 2020 0.92 [0.67; 1.28]
Mobarak S (DISCOVER), 2021 1.10 [0.77; 1.57]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2020 1.09 [0.97; 1.23]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.59 [0.33; 1.06]
Sakoulas, 2020 0.29 [0.03; 3.13]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shahbaznejad, 2020 2.21 [0.07; 67.87]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.56 [0.34; 7.13]
Tang X, 2020 0.98 [0.93; 1.02]
University of Minnesota, 2020 1.29 [0.51; 3.26]
Veiga, 2021 2.70 [0.92; 7.92]
Zhang, 2020 0.50 [0.17; 1.50]
 0.92 [0.88 ; 0.96 ] Abdulamir, 2021, Abuhasira, 2021, ACTT-2 (Kalil), 2020, AlQahtani, 2020, Aman, 2021, ASCOT, 2021, Bennett-Guerrero, 2021, CAN-COVID, 2020, Co-CLARITY, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, FACCT Trial, 2021, Fragoso-Saavedra (PISCO), 2020, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Horby, 2021, HYDRA (Hernandez-Cardenas), 2021, I-TECH (Lim), 2022, ITAC, 2022, Jamaati, 2021, Kalil (ACTT-3), 2021, Kirenga, 2021, Krolewiecki, 2020, Lanzoni, 2021, Li, 2020, LIFESAVER, 2021, Mahajan, 2021, Menichetti, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04528368, 2021, NCT04577534 (COVIDSTORM), 0, NIH NIAID ACTT-1, 2020, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Raman, 2021, RAPID (Sholzberg), 2021, RECOVER, 2021, RECOVERY, 2020, RECOVERY, 2022, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, Rosas (REMDACTA), 2021, Rutgers, 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shahbaznejad, 2020, Shashi Bhushan, 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, SOLIDARITY (WHO study) HCQ, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Tabarsi, 2020, Talaschian, 2021, Tang X, 2020, University of Minnesota, 2020, Veiga, 2021, Zhang, 2020 91 24% 98,080 moderate critical death or transfer to ICUdetailed results  BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
Gunst JD, 2021 0.55 [0.26; 1.17]
Lopardo, 2021 0.65 [0.35; 1.22]
RAPID (Sholzberg), 2021 0.70 [0.44; 1.12]
RECOVERY, 2020 1.09 [0.99; 1.20]
 0.84 [0.62 ; 1.13 ] BACC Bay Tocilizumab Trial, 2020, Gunst JD, 2021, Lopardo, 2021, RAPID (Sholzberg), 2021, RECOVERY, 2020 5 53% 5,989 moderate serious deathsdetailed results  Abd-Elsalam, 2020 1.21 [0.36; 4.12]
Abdulamir, 2021 1.00 [0.20; 5.12]
ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
ASCOT, 2021 0.60 [0.06; 5.99]
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.88 [0.64; 1.20]
BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
CAN-COVID, 2020 0.67 [0.30; 1.50]
Cao, 2020 0.71 [0.36; 1.40]
CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45]
CAPE-COVID, 2020 0.45 [0.20; 1.02]
CAPSID, 2021 0.84 [0.28; 2.50]
CCAP-2, 2021 2.03 [0.61; 6.77]
Chen, 2020 0.56 [0.01; 30.20]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 0.64 [0.18; 2.24]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
COALIZAO ACTION, 2021 1.55 [0.90; 2.70]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59]
CONFIDENT, 2020 0.84 [0.52; 1.37]
ConPlas-19, 2020 0.46 [0.19; 1.15]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COP-COVID-19, 2021 0.96 [0.36; 2.56]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-ANA-1, 2021 0.97 [0.46; 2.04]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Dabbous HM, 2020 0.51 [0.02; 15.41]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
EMPACTA, 2020 1.13 [0.54; 2.40]
Entrenas (Pilot Calcifediol), 2020 0.12 [0.01; 2.79]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
FACCT Trial, 2021 0.96 [0.44; 2.08]
Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
Fu, 2020 1.00 [0.02; 51.66]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.62 [0.33; 1.17]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
Gonzalez (HCQ), 2020 0.33 [0.06; 1.78]
Gonzalez (IVER), 2020 0.83 [0.23; 3.02]
GRECCO-19, 2020 0.21 [0.02; 1.97]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
Gunst JD, 2021 0.70 [0.20; 2.49]
Hashim A, 2020 0.48 [0.11; 1.99]
Holm K, 2021 0.49 [0.08; 2.89]
Horby, 2021 1.01 [0.93; 1.10]
HYCOVID, 2020 0.54 [0.21; 1.40]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
INSPIRATION, 2021 1.09 [0.78; 1.53]
ITAC, 2022 0.80 [0.42; 1.52]
Jamaati, 2021 1.19 [0.38; 3.72]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Khamis, 2020 0.83 [0.23; 2.96]
Kirenga, 2021 1.25 [0.46; 3.39]
Kirti, 2021 0.12 [0.01; 2.36]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Lanzoni, 2021 0.11 [0.01; 0.93]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
Li, 2020 0.59 [0.22; 1.59]
Libster, 2020 0.50 [0.09; 2.71]
LIFESAVER, 2021 2.00 [0.16; 24.66]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
Lopardo, 2021 0.57 [0.24; 1.37]
Lou (FAVIPIRAVIR), 2020 1.12 [0.02; 62.74]
Lou Y, 2020 1.00 [0.02; 55.80]
Mahajan, 2021 1.23 [0.34; 4.42]
Menichetti, 2021 0.75 [0.37; 1.53]
Metcovid, 2020 0.92 [0.67; 1.28]
Mobarak S (DISCOVER), 2021 1.15 [0.80; 1.67]
Murai, 2020 1.53 [0.53; 4.43]
NCT04385199, 2021 0.75 [0.15; 3.77]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04442191, 2021 0.11 [0.00; 143.68]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04542694, 2020 1.00 [0.02; 50.90]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
ORCHID, 2020 1.07 [0.54; 2.11]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
ProPAC-COVID, 2021 0.08 [0.00; 8.65]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
Rasheed, 2020 0.13 [0.01; 1.09]
RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2020 1.09 [0.97; 1.23]
RECOVERY, 2020 1.03 [0.91; 1.17]
RECOVERY, 2021 0.85 [0.76; 0.95]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.08 [0.85; 1.38]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
Sadeghi , 2020 0.56 [0.12; 2.56]
Sakoulas, 2020 0.29 [0.03; 3.13]
Salehzadeh, 2020 1.00 [0.02; 51.41]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Sekhavati, 2020 0.49 [0.02; 14.80]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55]
SOLIDARITY (interferon), 2020 1.16 [0.96; 1.40]
SOLIDARITY (lopi/rito), 2020 1.00 [0.79; 1.26]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.25 [0.30; 5.14]
Tang X, 2020 0.98 [0.93; 1.02]
TEACH, 2020 1.07 [0.34; 3.37]
Udwadia, 2020 0.50 [0.02; 15.03]
University of Minnesota, 2020 0.68 [0.11; 4.16]
Veiga, 2021 2.70 [0.92; 7.92]
Yakoot, 2020 0.38 [0.07; 2.08]
Zhang, 2020 0.50 [0.17; 1.50]
 0.91 [0.88 ; 0.95 ] Abd-Elsalam, 2020, Abdulamir, 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, AlQahtani, 2020, Aman, 2021, ASCOT, 2021, ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, BACC Bay Tocilizumab Trial, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, CAN-COVID, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, CAPE-COVID, 2020, CAPSID, 2021, CCAP-2, 2021, Chen, 2020, Co-CLARITY, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COALIZAO ACTION, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConCOVID (Gharbharan et al.), 2020, CONFIDENT, 2020, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COP-COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Dabbous HM, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, DEXA-COVID19, 2020, EMPACTA, 2020, Entrenas (Pilot Calcifediol), 2020, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, FACCT Trial, 2021, Fragoso-Saavedra (PISCO), 2020, Fu, 2020, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, GRECCO-19, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Hashim A, 2020, Holm K, 2021, Horby, 2021, HYCOVID, 2020, HYDRA (Hernandez-Cardenas), 2021, I-TECH (Lim), 2022, INSPIRATION, 2021, ITAC, 2022, Jamaati, 2021, Kalil (ACTT-3), 2021, Khamis, 2020, Kirenga, 2021, Kirti, 2021, Krolewiecki, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, Libster, 2020, LIFESAVER, 2021, LIVE-AIR (Temesgen), 2021, Lopardo, 2021, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Mahajan, 2021, Menichetti, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, Murai, 2020, NCT04385199, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04442191, 2021, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04523831 (Mahmud), 2020, NCT04528368, 2021, NCT04542694, 2020, NCT04577534 (COVIDSTORM), 0, NIH NIAID ACTT-1, 2020, NO COVID-19 (Lyngbakken), 2020, NOR-Solidarity (hydroxychloroquine), 2021, ORCHID, 2020, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, ProPAC-COVID, 2021, Rahmani, 2020, Raman, 2021, RAPID (Sholzberg), 2021, Rasheed, 2020, RCT-TCZ-COVID-19, 2021, RECOVER, 2021, RECOVERY, 2020, RECOVERY, 2020, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021, Rosas (REMDACTA), 2021, Rutgers, 2021, Sadeghi , 2020, Sakoulas, 2020, Salehzadeh, 2020, SAVE-MORE, 2021, Sekhavati, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, SOLIDARITY (interferon), 2020, SOLIDARITY (lopi/rito), 2020, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Steroids-SARI, 2020, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tabarsi, 2020, Talaschian, 2021, Tang X, 2020, TEACH, 2020, Udwadia, 2020, University of Minnesota, 2020, Veiga, 2021, Yakoot, 2020, Zhang, 2020 168 19% 146,116 moderate critical deaths (time to event analysis only)detailed results  ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 0.64 [0.18; 2.24]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConPlas-19, 2020 0.46 [0.19; 1.15]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
Gunst JD, 2021 0.70 [0.20; 2.49]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lanzoni, 2021 0.11 [0.01; 0.93]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
PlasmAr, 2020 0.93 [0.47; 1.85]
RECOVERY, 2020 1.09 [0.97; 1.23]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
Talaschian, 2021 1.25 [0.30; 5.14]
Zhang, 2020 0.50 [0.17; 1.50]
 0.88 [0.81 ; 0.96 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTT-2 (Kalil), 2020, Baldeon, 2022, Bennett-Guerrero, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, COV-BARRIER, 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, DAWN-Plasma, 2021, Fragoso-Saavedra (PISCO), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lanzoni, 2021, LIVE-AIR (Temesgen), 2021, NIH NIAID ACTT-1, 2020, NOR-Solidarity (hydroxychloroquine), 2021, PlasmAr, 2020, RECOVERY, 2020, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Talaschian, 2021, Zhang, 2020 36 42% 50,123 moderate critical clinical deteriorationdetailed results  BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64]
CAPSID, 2021 0.63 [0.29; 1.40]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 0.99 [0.57; 1.72]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
COALIZAO ACTION, 2021 1.35 [0.85; 2.15]
CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58]
ConPlas-19, 2020 1.00 [0.65; 1.53]
CONTAIN COVID-19, 2021 0.94 [0.75; 1.18]
CORIMUNO-ANA-1, 2021 0.89 [0.42; 1.92]
CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
COV-BARRIER, 2021 1.12 [0.58; 2.16]
ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57]
ELACOI (Standard of care), 2020 0.86 [0.06; 11.36]
EMPACTA, 2020 0.55 [0.33; 0.92]
GRECCO-19, 2020 0.11 [0.01; 1.08]
Hashim A, 2020 0.40 [0.10; 1.63]
I-TECH (Lim), 2022 1.25 [0.87; 1.80]
Kirenga, 2021 0.91 [0.38; 2.17]
Li T, 2020 0.48 [0.01; 27.44]
Libster, 2020 0.52 [0.29; 0.94]
NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84]
RAPID (Sholzberg), 2021 0.69 [0.43; 1.10]
RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
Shu, 2020 0.27 [0.01; 5.58]
Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77]
STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
Tang X, 2020 1.00 [0.13; 7.45]
TEACH, 2020 1.80 [0.62; 5.21]
Zhang, 2020 0.40 [0.10; 1.65]
 0.78 [0.66 ; 0.92 ] BACC Bay Tocilizumab Trial, 2020, CAP-China (Wang et al.), 2020, CAPSID, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALIZAO ACTION, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, COV-BARRIER, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, EMPACTA, 2020, GRECCO-19, 2020, Hashim A, 2020, I-TECH (Lim), 2022, Kirenga, 2021, Li T, 2020, Libster, 2020, NCT04523831 (Mahmud), 2020, RAPID (Sholzberg), 2021, RCT-TCZ-COVID-19, 2021, SAVE-MORE, 2021, Shu, 2020, Soin AS (COVINTOC), 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020, TEACH, 2020, Zhang, 2020 34 49% 7,888 moderate low clinical improvementdetailed results  ACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20]
ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
AVIFAVIR, 2020 0.53 [0.13; 2.19]
BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
CAN-COVID, 2020 1.39 [0.76; 2.54]
Cao, 2020 1.31 [0.94; 1.83]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
CAPSID, 2021 1.58 [0.71; 3.49]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 0.81 [0.54; 1.22]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
ConPlas-19, 2020 0.95 [0.60; 1.52]
COV-BARRIER, 2021 1.25 [1.04; 1.50]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Dongsheng Wang, 2020 2.37 [0.40; 13.96]
EMPACTA, 2020 1.15 [0.90; 1.47]
Ghandehari, 2020 1.31 [1.00; 1.71]
GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74]
GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49]
Gunst JD, 2021 1.14 [0.83; 1.57]
ITAC, 2022 1.06 [0.77; 1.45]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Li, 2020 1.40 [0.79; 2.49]
Lopardo, 2021 1.61 [0.75; 3.49]
Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
NCT04542694, 2020 2.10 [1.04; 4.24]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
ORCHID, 2020 1.02 [0.73; 1.42]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 0.83 [0.67; 1.03]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
Tang X, 2020 1.04 [0.67; 1.62]
Udwadia, 2020 1.75 [1.10; 2.79]
 1.16 [1.08 ; 1.24 ] ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, AVIFAVIR, 2020, BACC Bay Tocilizumab Trial, 2020, Bennett-Guerrero, 2021, CAN-COVID, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, CAPSID, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, ConPlas-19, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Dongsheng Wang, 2020, EMPACTA, 2020, Ghandehari, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Li, 2020, Lopardo, 2021, Lou (FAVIPIRAVIR), 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (tocilizumab), 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021, Ruzhentsova T, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020, Tang X, 2020, Udwadia, 2020 49 48% 16,424 moderate critical clinical improvement (14-day)detailed results  ACTT-2 (Kalil), 2020 1.30 [1.03; 1.64]
AVIFAVIR, 2020 0.53 [0.13; 2.19]
Cao, 2020 1.94 [1.09; 3.48]
CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28]
Chen, 2020 0.56 [0.13; 2.48]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1.01 [0.58; 1.76]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
COV-BARRIER, 2021 1.28 [1.05; 1.56]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47]
GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44]
Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
Li, 2020 2.27 [0.90; 5.72]
Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
Lou Y, 2020 1.50 [0.26; 8.82]
ORCHID, 2020 1.02 [0.73; 1.42]
Pandit, 2021 8.77 [0.94; 81.67]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
Ruzhentsova T, 2020 1.28 [1.05; 1.56]
Sadeghi , 2020 3.63 [1.02; 12.93]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
Tang X, 2020 1.33 [0.57; 3.11]
 1.15 [1.00 ; 1.31 ] ACTT-2 (Kalil), 2020, AVIFAVIR, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Kalil (ACTT-3), 2021, Li, 2020, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, ORCHID, 2020, Pandit, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Ruzhentsova T, 2020, Sadeghi , 2020, Shashi Bhushan, 2021, Shu, 2020, Tang X, 2020 26 47% 8,874 moderate low clinical improvement (21-day)detailed results  Li T, 2020 2.09 [0.04; 119.96]
 2.09 [0.04 ; 119.96 ] Li T, 2020 1 0% 18 NA not evaluable clinical improvement (28-day)detailed results  Abuhasira, 2021 1.70 [0.52; 5.49]
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.27 [1.03; 1.57]
Bennett-Guerrero, 2021 1.02 [0.25; 4.20]
Cao, 2020 1.59 [0.84; 3.03]
CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39]
COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04]
COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42]
GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17]
Li, 2020 1.42 [0.65; 3.10]
NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76]
ORCHID, 2020 0.97 [0.69; 1.37]
O’Donnell, 2021 1.38 [0.73; 2.61]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Ruzhentsova T, 2020 1.11 [0.96; 1.29]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 3.68 [0.18; 75.54]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 3.15 [1.39; 7.14]
Udwadia, 2020 1.75 [1.10; 2.79]
 1.28 [1.12 ; 1.46 ] Abuhasira, 2021, ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, Bennett-Guerrero, 2021, Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li, 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, Pouladzadeh, 2021, Ruzhentsova T, 2020, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020, Udwadia, 2020 22 41% 7,084 moderate critical clinical improvement (7-day)detailed results  ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
Cao, 2020 3.16 [0.62; 16.06]
CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35]
COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40]
GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53]
GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09]
ITAC, 2022 1.06 [0.77; 1.45]
Kirti, 2021 0.90 [0.77; 1.06]
Li, 2020 0.98 [0.27; 3.58]
Lou Y, 2020 1.00 [0.05; 18.57]
NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93]
NCT04542694, 2020 2.10 [1.04; 4.24]
ORCHID, 2020 1.16 [0.84; 1.61]
Ruzhentsova T, 2020 1.50 [1.02; 2.21]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
Shu, 2020 6.72 [1.50; 30.07]
 1.21 [1.02 ; 1.43 ] ACTIV-3/TICO LY-CoV555 , 2020, Cao, 2020, CAP-China (Wang et al.), 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, ITAC, 2022, Kirti, 2021, Li, 2020, Lou Y, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, ORCHID, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021, Shu, 2020 17 53% 4,554 moderate critical clinical improvement (time to event analysis only)detailed results  Abuhasira, 2021 1.22 [0.70; 2.14]
ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
Cao, 2020 1.31 [0.94; 1.83]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
ConPlas-19, 2020 0.95 [0.60; 1.52]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
EMPACTA, 2020 1.15 [0.90; 1.47]
FACCT Trial, 2021 0.85 [0.62; 1.16]
GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44]
GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42]
Gunst JD, 2021 1.14 [0.83; 1.57]
HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
Li, 2020 1.40 [0.79; 2.49]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
ORCHID, 2020 0.97 [0.69; 1.36]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
Rahmani, 2020 3.41 [1.33; 8.73]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Shinkai, 2021 1.40 [0.91; 2.15]
Tang X, 2020 1.04 [0.67; 1.62]
Udwadia, 2020 1.75 [1.10; 2.79]
 1.16 [1.09 ; 1.24 ] Abuhasira, 2021, ACTT-2 (Kalil), 2020, Bennett-Guerrero, 2021, Cao, 2020, CAP-China (Wang et al.), 2020, ConPlas-19, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, EMPACTA, 2020, FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, NCT04523831 (Mahmud), 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, Ruzhentsova T, 2020, Shinkai, 2021, Tang X, 2020, Udwadia, 2020 28 24% 7,743 moderate critical death or ventilationdetailed results  ACTT-2 (Kalil), 2020 0.69 [0.50; 0.95]
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.82 [0.63; 1.07]
BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
CAPE-COVID, 2020 0.71 [0.37; 1.35]
COLCOVID, 2021 0.83 [0.67; 1.02]
CONCOR-1, 2021 1.16 [0.94; 1.43]
ConPlas-19, 2020 0.94 [0.86; 1.02]
CORIMUNO-ANA-1, 2021 0.97 [0.62; 1.52]
CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
DAWN-Plasma, 2021 1.01 [0.64; 1.59]
EMPACTA, 2020 0.56 [0.32; 0.97]
Fragoso-Saavedra (PISCO), 2020 0.46 [0.22; 0.96]
Gonzalez (HCQ), 2020 0.69 [0.22; 2.21]
Gonzalez (IVER), 2020 0.89 [0.30; 2.64]
HYCOVID, 2020 1.12 [0.45; 2.79]
LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
Menichetti, 2021 0.88 [0.59; 1.32]
ORCHID, 2020 1.13 [0.60; 2.13]
RAPID (Sholzberg), 2021 0.59 [0.34; 1.02]
RECOVERY, 2020 1.14 [1.03; 1.27]
RECOVERY, 2021 0.85 [0.78; 0.93]
RECOVERY, 2022 0.90 [0.81; 0.99]
RECOVERY (AZI, Horby), 2020 0.95 [0.87; 1.03]
RECOVERY (colchicine), 2021 1.02 [0.96; 1.09]
RECOVERY (plasma), 2021 0.99 [0.93; 1.05]
RECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92]
RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
Rutgers, 2021 0.65 [0.43; 0.99]
SOLIDARITY (interferon), 2020 1.05 [0.90; 1.23]
SOLIDARITY (remdesivir), 2020 0.97 [0.85; 1.10]
SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97]
Synairgen SG016, 2020 0.38 [0.09; 1.63]
Veiga, 2021 1.54 [0.65; 3.63]
 0.92 [0.88 ; 0.97 ] ACTT-2 (Kalil), 2020, ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, BACC Bay Tocilizumab Trial, 2020, CAPE-COVID, 2020, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, DAWN-Plasma, 2021, EMPACTA, 2020, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYCOVID, 2020, LIVE-AIR (Temesgen), 2021, Menichetti, 2021, ORCHID, 2020, RAPID (Sholzberg), 2021, RECOVERY, 2020, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, SOLIDARITY (interferon), 2020, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Veiga, 2021 37 53% 76,507 moderate critical hospital dischargedetailed results  ACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20]
CAPE-COVID, 2020 1.67 [0.87; 3.19]
ConPlas-19, 2020 1.02 [0.82; 1.28]
DAWN-Plasma, 2021 1.06 [0.87; 1.30]
EMPACTA, 2020 1.16 [0.90; 1.49]
FACCT Trial, 2021 0.88 [0.64; 1.21]
Fragoso-Saavedra (PISCO), 2020 1.13 [0.82; 1.55]
Gonzalez (HCQ), 2020 1.38 [0.46; 4.16]
Gonzalez (IVER), 2020 0.71 [0.15; 3.40]
HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42]
Kirti, 2021 1.20 [0.73; 1.98]
Li T, 2020 10.00 [1.03; 97.50]
Murai, 2020 0.99 [0.71; 1.38]
Rahmani, 2020 3.44 [0.64; 18.49]
RECOVERY, 2020 0.98 [0.91; 1.05]
RECOVERY (Aspirin), 2022 1.06 [1.02; 1.10]
RECOVERY (AZI, Horby), 2020 1.04 [0.98; 1.10]
RECOVERY (colchicine), 2021 0.98 [0.94; 1.03]
RECOVERY (plasma), 2021 0.99 [0.92; 1.07]
RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31]
RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
Synairgen SG016, 2020 1.63 [0.61; 4.35]
Udwadia, 2020 1.41 [0.97; 2.03]
University of Minnesota, 2020 0.64 [0.37; 1.11]
 1.03 [0.99 ; 1.08 ] ACTIV-3/TICO LY-CoV555 , 2020, CAPE-COVID, 2020, ConPlas-19, 2020, DAWN-Plasma, 2021, EMPACTA, 2020, FACCT Trial, 2021, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYDRA (Hernandez-Cardenas), 2021, Kirti, 2021, Li T, 2020, Murai, 2020, Rahmani, 2020, RECOVERY, 2020, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Rosas (REMDACTA), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020, Udwadia, 2020, University of Minnesota, 2020 28 53% 66,056 moderate low hospitalizationdetailed results  Jagannathan, 2020 1.00 [0.14; 7.34]
University of Minnesota, 2020 1.63 [0.94; 2.85]
 1.58 [0.92 ; 2.70 ] Jagannathan, 2020, University of Minnesota, 2020 2 0% 325 moderate not evaluable mechanical ventilationdetailed results  Abuhasira, 2021 1.62 [0.41; 6.39]
ACTT-2 (Kalil), 2020 0.64 [0.44; 0.93]
AlQahtani, 2020 0.67 [0.22; 2.02]
CAPE-COVID, 2020 0.95 [0.44; 2.04]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1.77 [0.81; 3.87]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COPLA-II trial, 2020 0.58 [0.37; 0.92]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Fragoso-Saavedra (PISCO), 2020 0.85 [0.27; 2.62]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.70 [0.52; 0.95]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.85 [0.68; 1.06]
GRECCO-19, 2020 0.17 [0.02; 1.48]
GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30]
GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45]
Gunst JD, 2021 2.27 [0.62; 8.26]
Holm K, 2021 0.39 [0.01; 12.68]
I-TECH (Lim), 2022 0.41 [0.13; 1.30]
Jamaati, 2021 1.38 [0.45; 4.20]
Kirti, 2021 0.20 [0.00; 8.69]
Li T, 2020 0.40 [0.04; 3.90]
Lou Y, 2020 2.11 [0.06; 70.98]
Mahajan, 2021 2.27 [0.39; 13.27]
Metcovid, 2020 1.19 [0.56; 2.49]
Mobarak S (DISCOVER), 2021 1.52 [0.72; 3.19]
Murai, 2020 0.49 [0.21; 1.14]
NCT04397757, 2021 0.41 [0.13; 1.35]
O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
Rahmani, 2020 0.29 [0.05; 1.56]
RAPID (Sholzberg), 2021 0.70 [0.32; 1.54]
RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69]
RECOVERY, 2022 0.87 [0.74; 1.02]
RECOVERY (AZI, Horby), 2020 0.92 [0.79; 1.07]
RECOVERY (colchicine), 2021 1.04 [0.93; 1.16]
RECOVERY (plasma), 2021 0.98 [0.88; 1.09]
RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95]
Rutgers, 2021 0.65 [0.35; 1.24]
Sadeghi , 2020 0.37 [0.09; 1.58]
Sakoulas, 2020 0.19 [0.03; 1.11]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
Sekhavati, 2020 0.16 [0.01; 3.19]
Shahbaznejad, 2020 2.24 [0.19; 25.88]
Shu, 2020 0.59 [0.02; 14.04]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38]
SOLIDARITY (remdesivir), 2020 1.04 [0.87; 1.23]
Tabarsi, 2020 1.49 [0.59; 3.78]
Udwadia, 2020 0.06 [0.01; 0.83]
University of Minnesota, 2020 1.34 [0.66; 2.73]
Yakoot, 2020 0.38 [0.07; 2.08]
 0.88 [0.81 ; 0.96 ] Abuhasira, 2021, ACTT-2 (Kalil), 2020, AlQahtani, 2020, CAPE-COVID, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, COPLA-II trial, 2020, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Fragoso-Saavedra (PISCO), 2020, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Holm K, 2021, I-TECH (Lim), 2022, Jamaati, 2021, Kirti, 2021, Li T, 2020, Lou Y, 2020, Mahajan, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, Murai, 2020, NCT04397757, 2021, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, RAPID (Sholzberg), 2021, RCT-TCZ-COVID-19, 2021, RECOVERY, 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY dexamethasone, 2020, Rutgers, 2021, Sadeghi , 2020, Sakoulas, 2020, SAVE-MORE, 2021, Sekhavati, 2020, Shahbaznejad, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, SOLIDARITY (remdesivir), 2020, Tabarsi, 2020, Udwadia, 2020, University of Minnesota, 2020, Yakoot, 2020 54 25% 57,918 moderate critical mechanical ventilation (time to event analysis only)detailed results  CP-COVID-19, 2021 0.66 [0.25; 1.72]
DAWN-Plasma, 2021 1.08 [0.65; 1.80]
Fragoso-Saavedra (PISCO), 2020 0.81 [0.27; 2.42]
Gunst JD, 2021 0.69 [0.14; 3.42]
Udwadia, 2020 0.06 [0.01; 0.83]
 0.79 [0.47 ; 1.33 ] CP-COVID-19, 2021, DAWN-Plasma, 2021, Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, Udwadia, 2020 5 22% 993 moderate serious radiologic improvement (14-day)detailed results  ELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28]
ELACOI (Standard of care), 2020 0.18 [0.01; 3.99]
Jamaati, 2021 4.89 [1.15; 20.79]
Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28]
Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88]
Tabarsi, 2020 2.33 [0.45; 12.00]
 2.13 [1.30 ; 3.50 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Jamaati, 2021, Rashad (CLARI vs SoC), 2021, Rashad A (AZI vs SoC), 2021, Tabarsi, 2020 6 21% 584 moderate not evaluable radiologic improvement (7-day)detailed results  ELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09]
ELACOI (Standard of care), 2020 0.08 [0.00; 1.71]
 0.09 [0.01 ; 0.78 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020 2 0% 46 moderate not evaluable viral clearance detailed results  AVIFAVIR, 2020 3.89 [1.23; 12.29]
Chaccour, 2020 0.92 [0.77; 1.09]
CP-COVID-19, 2021 1.12 [0.16; 7.84]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Jagannathan, 2020 0.81 [0.56; 1.18]
Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
NCT04542694, 2020 13.03 [2.96; 57.24]
Pandit, 2021 2.33 [0.55; 9.83]
Raman, 2021 36.42 [10.85; 122.18]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
Tang X, 2020 1.78 [1.06; 3.00]
Udwadia, 2020 1.37 [0.94; 1.98]
 1.86 [1.28 ; 2.69 ] AVIFAVIR, 2020, Chaccour, 2020, CP-COVID-19, 2021, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Jagannathan, 2020, Lou (FAVIPIRAVIR), 2020, NCT04542694, 2020, Pandit, 2021, Raman, 2021, Ruzhentsova T, 2020, Salman, 2020, Shashi Bhushan, 2021, Tang X, 2020, Udwadia, 2020 16 78% 1,488 moderate critical viral clearance (time to event analysis only)detailed results  Jagannathan, 2020 0.81 [0.56; 1.18]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Tang X, 2020 1.78 [1.06; 3.00]
Udwadia, 2020 1.37 [0.94; 1.98]
 1.23 [0.91 ; 1.66 ] Jagannathan, 2020, Ruzhentsova T, 2020, Tang X, 2020, Udwadia, 2020 4 57% 524 moderate not evaluable viral clearance by day 14detailed results  AVIFAVIR, 2020 3.08 [0.62; 15.39]
Chen, 2020 1.42 [0.26; 7.76]
CP-COVID-19, 2021 1.51 [0.33; 6.94]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Kirenga, 2021 0.95 [0.76; 1.19]
Li T, 2020 1.00 [0.03; 34.67]
Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
Lou Y, 2020 0.12 [0.01; 2.86]
Pandit, 2021 10.23 [1.12; 93.35]
Raman, 2021 36.42 [10.85; 122.18]
Ruzhentsova T, 2020 0.99 [0.93; 1.06]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
 0.97 [0.48 ; 1.93 ] AVIFAVIR, 2020, Chen, 2020, CP-COVID-19, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kirenga, 2021, Li T, 2020, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Pandit, 2021, Raman, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 2021 13 93% 2,053 moderate low viral clearance by day 7detailed results  AVIFAVIR, 2020 3.89 [1.23; 12.29]
Chaccour, 2020 0.92 [0.77; 1.09]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91]
ELACOI (Standard of care), 2020 0.67 [0.10; 4.58]
Kirenga, 2021 0.87 [0.65; 1.16]
Kirti, 2021 0.80 [0.43; 1.50]
Lou Y, 2020 1.50 [0.26; 8.82]
Pandit, 2021 2.33 [0.55; 9.83]
Ruzhentsova T, 2020 1.05 [0.92; 1.20]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
 1.09 [0.88 ; 1.34 ] AVIFAVIR, 2020, Chaccour, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kirenga, 2021, Kirti, 2021, Lou Y, 2020, Pandit, 2021, Ruzhentsova T, 2020, Salman, 2020, Shashi Bhushan, 2021 12 48% 973 moderate low ICU admissiondetailed results  Abd-Elsalam, 2020 0.83 [0.35; 1.95]
Abuhasira, 2021 1.96 [0.51; 7.52]
COL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69]
COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Entrenas (Pilot Calcifediol), 2020 0.03 [0.00; 0.27]
FACCT Trial, 2021 1.42 [0.79; 2.55]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.87 [0.69; 1.10]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.99 [0.56; 1.75]
Gunst JD, 2021 0.80 [0.34; 1.90]
I-TECH (Lim), 2022 0.78 [0.27; 2.23]
Khamis, 2020 1.03 [0.35; 3.03]
Kirti, 2021 0.90 [0.30; 2.70]
Libster, 2020 0.33 [0.07; 1.58]
Lopardo, 2021 0.67 [0.35; 1.28]
Lou (FAVIPIRAVIR), 2020 5.43 [0.21; 139.89]
Lou Y, 2020 2.11 [0.06; 70.98]
Murai, 2020 0.71 [0.37; 1.37]
ProPAC-COVID, 2021 1.24 [0.26; 5.80]
Rahmani, 2020 0.37 [0.14; 1.00]
RAPID (Sholzberg), 2021 0.79 [0.48; 1.30]
Rutgers, 2021 0.96 [0.55; 1.68]
Sekhavati, 2020 0.25 [0.05; 1.28]
Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64]
Tabarsi, 2020 0.56 [0.18; 1.74]
Tang X, 2020 1.00 [0.13; 7.45]
Yakoot, 2020 0.38 [0.07; 2.08]
 0.82 [0.70 ; 0.95 ] Abd-Elsalam, 2020, Abuhasira, 2021, COL-COVID (Pascual-Figal), 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Entrenas (Pilot Calcifediol), 2020, FACCT Trial, 2021, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Gunst JD, 2021, I-TECH (Lim), 2022, Khamis, 2020, Kirti, 2021, Libster, 2020, Lopardo, 2021, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Murai, 2020, ProPAC-COVID, 2021, Rahmani, 2020, RAPID (Sholzberg), 2021, Rutgers, 2021, Sekhavati, 2020, Soin AS (COVINTOC), 2021, Tabarsi, 2020, Tang X, 2020, Yakoot, 2020 29 6% 4,639 moderate critical Major thrombotic events or deathdetailed results  REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.04 [0.80; 1.36]
 1.04 [0.80 ; 1.36 ] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1 0% 1,091 NA not evaluable off oxygenationdetailed results  HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51]
 0.98 [0.64 ; 1.51 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable recoverydetailed results  Abdulamir, 2021 1.00 [0.20; 5.12]
ACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32]
ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37]
ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46]
COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
Crippa (CANDIDATE), 2021 0.54 [0.15; 1.94]
GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37]
GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45]
Gunst JD, 2021 1.18 [0.87; 1.61]
Lanzoni, 2021 3.46 [1.05; 11.35]
Mobarak S (DISCOVER), 2021 0.97 [0.89; 1.05]
Synairgen SG016, 2020 2.19 [1.03; 4.67]
Talaschian, 2021 0.64 [0.14; 2.92]
Yakoot, 2020 1.60 [1.00; 2.55]
 1.12 [1.01 ; 1.23 ] Abdulamir, 2021, ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020, COV-BARRIER (critically ill), 2022, Crippa (CANDIDATE), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Lanzoni, 2021, Mobarak S (DISCOVER), 2021, Synairgen SG016, 2020, Talaschian, 2021, Yakoot, 2020 14 33% 3,707 moderate critical AE leading to drug discontinuationdetailed results  CAP-China (Wang et al.), 2020 2.43 [0.79; 7.45]
 2.43 [0.79 ; 7.45 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable cardiac arrestdetailed results  SOLIDARITY (WHO study) HCQ, 2020 1.92 [0.35; 10.49]
 1.92 [0.35 ; 10.49 ] SOLIDARITY (WHO study) HCQ, 2020 1 0% 1,853 NA not evaluable composite safety outcome detailed results  ACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11]
 1.56 [0.78 ; 3.11 ] ACTIV-3/TICO LY-CoV555 , 2020 1 0% 314 NA not evaluable related AE (TRAE)detailed results  Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
 1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable related SAE (TRSAE)detailed results  COALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11]
 1.24 [0.50 ; 3.11 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable serious adverse eventsdetailed results  BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
CAN-COVID, 2020 0.73 [0.45; 1.19]
Cao, 2020 0.52 [0.27; 1.01]
CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1.87 [0.36; 9.75]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10]
COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77]
CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
CONCOR-1, 2021 1.27 [1.02; 1.58]
ConPlas-19, 2020 0.89 [0.43; 1.86]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Dongsheng Wang, 2020 0.91 [0.02; 47.31]
GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23]
GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14]
Gunst JD, 2021 1.84 [0.79; 4.30]
ITAC, 2022 0.98 [0.66; 1.46]
Jagannathan, 2020 1.00 [0.14; 7.34]
Krolewiecki, 2020 1.00 [0.03; 31.59]
Lanzoni, 2021 0.10 [0.01; 0.69]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
Lou Y, 2020 2.25 [0.38; 13.47]
Murai, 2020 0.99 [0.02; 50.39]
NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58]
NCT04542694, 2020 6.15 [0.30; 124.49]
NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96]
ORCHID, 2020 1.26 [0.56; 2.84]
O’Donnell, 2021 0.64 [0.35; 1.17]
Pandit, 2021 0.95 [0.02; 50.33]
PlasmAr, 2020 1.40 [0.78; 2.51]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Ruzhentsova T, 2020 2.06 [0.09; 46.40]
Sadeghi , 2020 1.00 [0.02; 51.94]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
Shi, 2020 1.08 [0.04; 32.96]
Shinkai, 2021 2.80 [0.14; 56.95]
Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13]
Talaschian, 2021 7.93 [0.37; 171.38]
Udwadia, 2020 1.03 [0.02; 52.48]
Veiga, 2021 1.66 [0.60; 4.59]
Yakoot, 2020 1.02 [0.02; 52.72]
 0.99 [0.88 ; 1.12 ] BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, CONCOR-1, 2021, ConPlas-19, 2020, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, ITAC, 2022, Jagannathan, 2020, Krolewiecki, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Lou Y, 2020, Murai, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, Pandit, 2021, PlasmAr, 2020, Raman, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, Rosas (REMDACTA), 2021, Ruzhentsova T, 2020, Sadeghi , 2020, Sekine (PLACOVID), 2021, Shi, 2020, Shinkai, 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Udwadia, 2020, Veiga, 2021, Yakoot, 2020 46 18% 14,754 moderate low superinfectiondetailed results  ACTT-2 (Kalil), 2020 0.50 [0.32; 0.79]
CAPE-COVID, 2020 0.81 [0.49; 1.34]
Metcovid, 2020 0.98 [0.65; 1.47]
Rahmani, 2020 0.18 [0.02; 1.59]
 0.70 [0.46 ; 1.07 ] ACTT-2 (Kalil), 2020, CAPE-COVID, 2020, Metcovid, 2020, Rahmani, 2020 4 53% 1,641 low not evaluable acute kidney injury detailed results  Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1.18 [0.44; 3.18]
 1.18 [0.44 ; 3.18 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1 0% 345 NA not evaluable adverse eventsdetailed results  Chaccour, 2020 1.00 [0.20; 5.07]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 2.22 [1.43; 3.44]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78]
COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08]
COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Dongsheng Wang, 2020 9.64 [2.76; 33.75]
GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42]
GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80]
Gunst JD, 2021 0.80 [0.43; 1.51]
Jagannathan, 2020 1.33 [0.63; 2.78]
Kirenga, 2021 1.13 [0.50; 2.58]
Krolewiecki, 2020 1.53 [0.42; 5.58]
Lanzoni, 2021 0.18 [0.02; 1.95]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Murai, 2020 1.99 [0.07; 59.94]
NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77]
NCT04542694, 2020 1.00 [0.54; 1.85]
ORCHID, 2020 1.42 [0.87; 2.34]
Pandit, 2021 1.68 [0.47; 5.97]
Raman, 2021 1.36 [0.56; 3.30]
RECOVERY, 2020 1.36 [0.98; 1.90]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Ruzhentsova T, 2020 1.90 [0.96; 3.80]
Sakoulas, 2020 1.00 [0.02; 53.46]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Shi, 2020 0.88 [0.38; 2.03]
Shinkai, 2021 19.54 [7.77; 49.11]
Shu, 2020 2.48 [0.05; 132.54]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87]
TEACH, 2020 1.16 [0.55; 2.42]
Udwadia, 2020 6.36 [2.43; 16.65]
Veiga, 2021 1.65 [0.81; 3.37]
 1.44 [1.20 ; 1.73 ] Chaccour, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Jagannathan, 2020, Kirenga, 2021, Krolewiecki, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Murai, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, ORCHID, 2020, Pandit, 2021, Raman, 2021, RECOVERY, 2020, Rosas (REMDACTA), 2021, Ruzhentsova T, 2020, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shi, 2020, Shinkai, 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, TEACH, 2020, Udwadia, 2020, Veiga, 2021 36 58% 11,672 moderate low arrhythmiadetailed results  Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 2.24 [0.23; 21.69]
RECOVERY (AZI, Horby), 2020 0.90 [0.71; 1.15]
Sekhavati, 2020 0.98 [0.02; 50.38]
 0.91 [0.72 ; 1.15 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, RECOVERY (AZI, Horby), 2020, Sekhavati, 2020 3 0% 8,290 moderate not evaluable deep vein thrombosisdetailed results  CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81]
 0.62 [0.23 ; 1.64 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable elevated liver enzymesdetailed results  CAP-China (Wang et al.), 2020 0.36 [0.13; 1.01]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 3.48 [1.40; 8.64]
NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18]
 0.95 [0.29 ; 3.10 ] CAP-China (Wang et al.), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, NIH NIAID ACTT-1, 2020 3 84% 1,712 moderate not evaluable hyperbilirubinemiadetailed results  CAP-China (Wang et al.), 2020 1.09 [0.42; 2.79]
NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34]
 0.97 [0.48 ; 1.93 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 low not evaluable long QTdetailed results  Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 9.79 [1.27; 75.50]
COALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43]
 2.39 [0.24 ; 23.87 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 80% 613 moderate not evaluable Major bleedingdetailed results  ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.80 [0.88; 3.67]
COALIZAO ACTION, 2021 2.50 [0.78; 8.06]
INSPIRATION, 2021 1.83 [0.53; 6.34]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.48 [0.74; 2.98]
 1.75 [1.14 ; 2.69 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, COALIZAO ACTION, 2021, INSPIRATION, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 4 0% 4,494 moderate not evaluable pulmonary embolismdetailed results  CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80]
 0.82 [0.20 ; 3.29 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable renal impairmentdetailed results  CAP-China (Wang et al.), 2020 1.01 [0.03; 30.33]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86]
COALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11]
NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61]
 1.26 [0.95 ; 1.67 ] CAP-China (Wang et al.), 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, NIH NIAID ACTT-1, 2020 4 0% 2,066 moderate not evaluable Thromboembolic  eventsdetailed results  Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 0.89 [0.31; 2.55]
COALIZAO ACTION, 2021 0.73 [0.41; 1.29]
INSPIRATION, 2021 1.07 [0.76; 1.49]
 0.96 [0.73 ; 1.27 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, COALIZAO ACTION, 2021, INSPIRATION, 2021 3 0% 1,521 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2025-10-31 03:56 +01:00 
                TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); 
                k: number of studies; n: total number of patients;
                ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
                
         
        
        
        
            pathologies: 95,94,90,91
    - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
    - roots T: 290